
Our vision at LDNscience® is to increase awareness and accessibility of the FDA-approved drug naltrexone, which in low doses (called LDN or Low Dose Naltrexone) has been clinically proven to be effective against multiple sclerosis, fibromyalgia, Crohn’s disease and many other chronic conditions such as thyroid disorders, restless legs syndrome, chronic pain to name but a few.

Although LDN is drastically improving the lives of hundreds of thousands of people, major pharmaceutical companies overlook LDN due to its low cost and thus, lack of commercial appeal. That’s why we launched a patient-driven initiative, helping patients discover this low-cost life-saving treatment, inform their physicians and spread the word to empower other patients to do the same.

What we’ve accomplished in the past 15 years:
- Launched and supported the largest patient-led drug repurposing* initiative in history
- Initiated the first clinical trial of LDN in 2002, spurring 50+ clinical trials and studies
- Helped thousands of doctors validate LDN as a viable treatment option
- Helped tens of thousands of patients connect with doctors who prescribe LDN
- Provided objective information to over a million patients
*Drug repurposing is the application of known drugs and compounds to treat new diseases.
Help us get more done!
Here’s how your donation will help:
All our donors will receive a mention on our Honorable Donors List - make sure to leave a message to be displayed in the comments or your wish to remain anonymous.
Donations can also be mailed to:
MedInsight Research Institute
1732 1st Ave #23222,
New York, NY 10128
About LDNscience®
LDNscience® is a project of MedInsight Research Institute, a nonprofit medical research organization that offers both doctors and patients access to life-saving information. At LDNscience®, we further LDN research to identify new uses of Low Dose Naltrexone to provide a safe and effective treatment for people living with autoimmune and other chronic diseases. We connect patients to doctors and suppliers and lead initiatives to provide additional regulatory approvals and insurance coverage.